One of the more recent webinars with Merit Cudkowicz (lead...

One of the more recent webinars with Merit Cudkowicz (lead researcher in charge of Healey) mentioned commencement of next drug most likely to begin January 2025. I would expect 6 month interim readouts to happen early 2026. I would imagine they would have liked to start sooner, but unfortunately given PAAs lack of funding that was not possible. Before they accept a new drug as one of their regimens, they need to be certain the funding will last until the end of the trial. For whatever reasons PAA was unable to convince them of that. No reason dwelling on what could have been. If the OLE results continue to show such promising data PAA could be in a much better situation than if they had an earlier start date. There are several drugs that could potentially be approved before the start date of January and be prescribed to patients participating in the phase 2/3 trial. Which may work synergistically and give mpl even better potential.